Introduction: Communication between medical staff and patients about treatment efficacy elicits expectations of benefit and improves treatment outcomes. While demonstrated in multiple studies via different research methodologies, uniform communication protocols have not been adopted in clinical practice. Here, we summarize the results of two sister studies aimed at bridging this gap. Methods: Women undergoing C-section (study 1, randomized controlled trial) and patients undergoing general or otolaryngologic surgeries (study 2, control group design) were recruited and assigned to the “regular communication” (RC) or “enhanced communication” (EC) arms. The EC arm received positive information about treatment, while the RC arm received no such information. In both studies, the primary outcome was change in pain intensity; in study 2, an additional outcome was morphine consumption. Results: Eighty women successfully completed study 1, and 102 patients successfully completed study 2. In both studies, significant time*group interactions were observed (p < 0.001). The analgesic effect was virtually twice as large in the EC arm compared to the RC arm. In study 2, in the last two timepoints of assessment, participants in the EC arm also consumed fewer doses of opioids than participants in the RC arm (p < 0.001). No significant differences were found in vital signs. Conclusions: We provide ecological evidence that positive information about treatment significantly decreases pain and opioid consumption during routine clinical care. This study and others could encourage healthcare providers to harness the powerful effects of patients’ expectations of benefit to improve analgesics outcomes and, potentially, the outcomes of other symptoms.

According to the additive model, the response to any given treatment is the sum of two effects: the underlying mechanism of the active treatment and the placebo response [1, 2]. An alternative, interactive model suggests that treatments and placebo responses interact and are not simply additive [1]. Various models notwithstanding the classical placebo theorem assert that the placebo effect stems mainly from patients’ expectations of benefit [3, 4], which could derive from conditioning, verbal suggestion, subtle cues, and other contextual elements [4‒8].

Extensive research on the analgesic placebo effect, mostly using experimental noxious paradigms in healthy individuals [9‒15] and chronic pain patients [11, 12, 15‒18], demonstrated large effects. Clinical pain is also heavily subject to the placebo response, which could account for about half of the response to effective analgesic treatments [19‒25]. Other creative studies demonstrated large effect sizes when patients received information about the study drug [20, 21, 26‒29] but not as part of routine clinical care.

Given that a significant portion of the analgesic response derives from the placebo effect, which could be enhanced by verbal suggestion, it is unclear why verbal suggestion has not been widely adopted in clinical practice. A possible explanation is the literature’s lack of direct evidence for the added value of enhancing patients’ expectations of benefit from analgesic treatments widely used in routine clinical care [30, 31].

Studies addressing these gaps are rare. A few demonstrated that the large effect of verbal suggestion on clinical pain could be clinically informative. However, those studies investigated clinical pain that does not represent a real clinical challenge, such as pain induced by injection [32] and for which the treatments are not part of routine analgesic clinical care [33].

In this study, we aimed to address this challenge by assessing the effects of a uniform verbal suggestion protocol during analgesic administration in a real-life clinical setting of acute postoperative pain. To this end, we conducted two studies: (1) randomized controlled trial, including women after C-section; and (2) a controlled group design, including participants recovering from general and otolaryngology surgeries.

Participants

In study 1, women scheduled for C-section in the maternal and newborn department at Carmel Hospital (Haifa, Israel) were invited to participate. In study 2, patients scheduled for general or otolaryngology surgery, under general anesthesia at the Ziv Medical Centre (Zafed, Israel), were invited to participate. Information about inclusion and exclusion criteria, power analyses, patients’ recruitment, and nurses’ involvement in the studies are found in the online supplementary material (for all online suppl. material, see https://doi.org/10.1159/000541810).

Study Medications

In each study, participants received the same pharmacological treatment (see online suppl. material), given as part of the routine analgesic protocol.

Study Intervention

The study intervention was the verbal suggestion communicated during treatment administration. In the “regular communication” (RC) arms, nurses applied the standard care protocol without any specific verbal instructions. In the “enhanced communication” (EC) arms, patients received positive information regarding the efficacy of the analgesic being administered. See online supplementary material for details on both studies’ verbal suggestions.

Main Outcomes

The primary endpoint in both studies was change in patients’ self-reported current pain intensity between the first and last assessment, on a 0–10 numerical pain scale (NPS): 0 (“no pain”) to 10 (“worst imaginable pain”). In study 1, pain was assessed at baseline (immediately before medication administration) and 1 h after analgesic administration. In study 2, pain intensity was assessed four times, every 10 min, beginning when participants regained consciousness. Those assessment times were chosen because they are part of routine clinical care protocol. For more information about the studies’ outcomes, see online supplementary material.

Study Design

Data were collected between March and September 2023 (study 1) and between June 2023 and February 2024 (study 2). Both study teams, located in separate hospitals, were unaware of the details or aims of the other study. For more information about the studies’ designs, see online supplementary material.

Statistical Analyses

Statistical analyses were conducted using the SPSS Statistical Package for the Social Sciences software (IBM SPSS Statistics, version 27.0) and the R Studio statistical software (v2023.12.1, R Core Team 2023) for visualization purposes. Descriptive statistics followed by normality tests and distribution asymmetry (skewness and kurtosis) revealed that the primary outcome measures were normally distributed, while some sociodemographic characteristics were not. Hence, parametric t tests and nonparametric Mann-Whitney and Fisher’s exact tests were used.

For study 1, consistent with our 2 × 2 study design, a repeated-measures analysis of variance (RM-ANOVA) with Greenhouse-Geisser correction was conducted, with time as within-subject and group as between-subject factors. Post hoc tests for pairwise comparisons and contrasts with Bonferroni corrections were employed. Study 2 used a 2*4 RM-ANOVA with time (T1, T2, T3, T4) as the within-subject and group as the between-subject factor. Pairwise comparisons and contrasts with Bonferroni corrections were employed.

To examine differences in opioid consumption between groups, χ2 tests of independence were employed. Additional supporting analyses are presented in the online supplementary material. Data are presented as mean ± SD for descriptive variables (in tables) and mean ± SEM for statistical tests (in the text); statistical significance was set at α value of <0.05 for all analyses.

In study 1, of 99 patients invited to participate, 80 completed the study: 38 in the RC arm; 42 in the EC arm (Fig. 1). In study 2, of 165 patients assessed for eligibility, 102 completed the study: 49 in the RC arm; 53 in the EC arm (Fig. 1). In both studies, EC and RC arms showed no significant sociodemographic differences (Table 1).

Fig. 1.

Consolidated Standards of Reporting Trials (CONSORT) diagram of patients’ enrolment in study 1 and study 2.

Fig. 1.

Consolidated Standards of Reporting Trials (CONSORT) diagram of patients’ enrolment in study 1 and study 2.

Close modal
Table 1.

Sociodemographic characteristics of all participants in the two studies

Demographic and medical characteristicsAll participantsRCECp value
Study 1 n = 80 n = 38 n = 42  
Age, mean ± SD, years 33.86±4.54 33.37±4.82 34.30±4.28 0.364 
BMI ± SD 30.48±5.07 30.28±5.14 30.66±5.07 0.741 
Number of past pregnancies ± SD 2.98±1.71 2.66±1.34 3.26±1.95 0.283 
Number of pregnancy failures ± SD 0.66±1.04 0.50±0.80 0.81±1.21 0.325 
Study 2 n = 102 n = 49 n = 53  
Age, mean ± SD, years 47.68±15.96 47.05±15.45 48.26±16. 54 0.705 
BMI ± SD 27.77±5.21 27.85±5.72 27.69±4.73 0.880 
Gender, N (%)    0.914 
 Male 63 (38.2) 30 (61.2) 32 (62.3)  
 Female 39 (61.8) 19 (38.8) 20 (37.7)  
Surgery procedure, N (%)    0.185 
 Lap. cholecystectomy 43 16 (32.7) 27 (50.9)  
 Hemorrhoidectomy 5 (10.2) 1 (1.9)  
 Hernia 42 21 (42.9) 21 (39.6)  
 Submucosal resection 4 (8.2) 2 (3.8)  
 Functional endoscopic sinus surgery 3 (6.1) 2 (3.8)  
Demographic and medical characteristicsAll participantsRCECp value
Study 1 n = 80 n = 38 n = 42  
Age, mean ± SD, years 33.86±4.54 33.37±4.82 34.30±4.28 0.364 
BMI ± SD 30.48±5.07 30.28±5.14 30.66±5.07 0.741 
Number of past pregnancies ± SD 2.98±1.71 2.66±1.34 3.26±1.95 0.283 
Number of pregnancy failures ± SD 0.66±1.04 0.50±0.80 0.81±1.21 0.325 
Study 2 n = 102 n = 49 n = 53  
Age, mean ± SD, years 47.68±15.96 47.05±15.45 48.26±16. 54 0.705 
BMI ± SD 27.77±5.21 27.85±5.72 27.69±4.73 0.880 
Gender, N (%)    0.914 
 Male 63 (38.2) 30 (61.2) 32 (62.3)  
 Female 39 (61.8) 19 (38.8) 20 (37.7)  
Surgery procedure, N (%)    0.185 
 Lap. cholecystectomy 43 16 (32.7) 27 (50.9)  
 Hemorrhoidectomy 5 (10.2) 1 (1.9)  
 Hernia 42 21 (42.9) 21 (39.6)  
 Submucosal resection 4 (8.2) 2 (3.8)  
 Functional endoscopic sinus surgery 3 (6.1) 2 (3.8)  

Treatment Efficacy in Study 1

Individual (Fig. 2a) and mean (Fig. 2b; online suppl. Table S1) pain scores before and after intervention for each arm are summarized. We found a significant main effect of time (F(1, 78) = 261.907, p < 0.001, η2 = 0.771) and a significant interaction of time*group (F(1, 78) = 22.142 p < 0.001, η2 = 0.221) but no main effect of group (F(1, 78) = 0.82, p = 0.775, η2 = 0.001). Both arms showed a statistically significant decrease in pain intensity reports from time 1 to time 2 (RC arm: mean difference ± SE = 2.29 ± 0.289, p < 0.001; 95% CI = [1.714, 2.865]; EC arm: mean difference ± SE = 4.17 ± 0.275, p < 0.001; 95% CI = [3.619, 4.714]). Nevertheless, significant differences in pain scores emerged between arms at both time 1 (mean difference ± SE = −0.85 ± 0.344, p = 0.016; 95% CI = [−1.530, −0.161]) and time 2 (mean difference ± SE = 1.03 ± 0.412, p = 0.014; 95% CI = [0.210, 1.852]) (Fig. 2c; online suppl. Table S1).

Fig. 2.

Changes in pain in each study and medication consumption in study 2. Treatment efficacy results for RC arms (blue) and EC arms (red) for study 1 (a–c) and study 2 (charts d–f). a Individual pain intensity scores at baseline and after intervention, study 1. b Mean pain scores at baseline and after intervention, study 1. c Magnitude of pain reduction (mean difference), study 1. d Individual pain intensity scores at time 1 (0 min) and time 4 (30 min, last timepoint of assessment), study 2. e Proportion of participants consuming analgesics (left side y-axis, bar plot represents percentage of opioid consumption across time) and mean pain intensity across time (right y-axis, line plot represents pain intensity), study 2. f Magnitude of pain reduction (mean difference between first and last assessments), study 2. Error bars signify confidence interval at 95%.

Fig. 2.

Changes in pain in each study and medication consumption in study 2. Treatment efficacy results for RC arms (blue) and EC arms (red) for study 1 (a–c) and study 2 (charts d–f). a Individual pain intensity scores at baseline and after intervention, study 1. b Mean pain scores at baseline and after intervention, study 1. c Magnitude of pain reduction (mean difference), study 1. d Individual pain intensity scores at time 1 (0 min) and time 4 (30 min, last timepoint of assessment), study 2. e Proportion of participants consuming analgesics (left side y-axis, bar plot represents percentage of opioid consumption across time) and mean pain intensity across time (right y-axis, line plot represents pain intensity), study 2. f Magnitude of pain reduction (mean difference between first and last assessments), study 2. Error bars signify confidence interval at 95%.

Close modal

Treatment Efficacy in Study 2

Figure 2d–f and online supplementary Table S2 depict the reduction in pain intensity and opioid consumption. Mauchly’s test indicated that the assumption of sphericity was violated (χ2(5) = 61.835, p < 0.001). Therefore, an RM-ANOVA with Greenhouse-Geisser correction revealed a significant main effect of time (F(2.209, 220.906) = 137.714, p < 0.001, η2 = 0.579) and significant interaction between time and arm (F(2.209, 220.906) = 19.033 p < 0.001, η2 = 0.160) but no significant main group effect (F(1, 100) = 1.691, p = 0.197).

Pain intensity was significantly decreased from baseline across all timepoints for both arms (largest p value = 0.030), except from time 1 to time 2 (p = 1.00) in the RC arm. Contrasts and pairwise comparisons showed that a significant between-arms difference was found in all timepoints (largest p value = 0.045), except at time 2 (p = 0.491) (online suppl. Table S2). Additional supporting results for both studies are found in online supplementary material.

Opioid Consumption in Study 2

Figure 2e depicts the medication consumption in the two arms over time. A χ2 test of independence revealed that medication consumption was significantly higher in the EC arm than that in the RC arm at time 1 (χ2(1, N = 102) = 11.838, p < 0.001), yet that this pattern was reversed, with significantly lower medication consumption in the EC arm than the RC arm, at time 3 (χ2(1, N = 102) = 11.831, p < 0.001) and time 4 (χ2(1, 102) = 11.663, p < 0.001). RM-ANOVAs revealed no significant main effects or interactions in any of the vital signs (see online suppl. Fig. 1S).

These studies aimed to ecologically assess the additive analgesic value of simple verbal protocols to elicit patients’ expectations of benefit from an analgesic treatment during routine clinical care. Despite differences in the studies’ design and treatments, the results are surprisingly similar: when treatment included positive comments about the medication’s efficacy, the analgesic effect was roughly twice that of routine medication administration. Moreover, at the last two assessments in study 2, the verbal protocol also reduced patients’ opioid consumption.

The significant effect of simple verbal suggestion is not surprising. Bingel et al. [10], using the open/hidden placebo paradigm [1], clearly demonstrated that the analgesia from remifentanil is more than doubled when participants are aware of its administration, compared to when they are unaware. Multiple studies have demonstrated the substantial effects of verbal suggestion on pain and other symptoms [15, 20, 21, 27, 34]. The effects are not limited to pain: both subjective and objective signs representing multiple physiological systems respond to verbal suggestion [1, 6, 35]. Given this comprehensive body of evidence, this simple approach has, surprisingly, not yet been adopted in routine clinical care.

Perhaps the main barrier to harnessing the power of this verbal protocol is the lack of direct real-world, ecological evidence outside of well-controlled experimental studies. Real-world results might be subject to biases and ambiguous conclusions. Our current studies might also have this limitation.

In both studies, verbal suggestion doubled the effect of analgesics routinely given for postoperative pain. This finding, however, is not conclusive. About half of the added analgesic effect observed in the EC arms of both studies was due to the greater baseline pain intensity in these arms. Possible explanations for this unexpected observation include poor or no randomization or poor or no blinding of participants and clinicians [1, 36‒39].

A more conservative interpretation could dismiss the baseline differences, noting that in both studies, pain was approximately 30% lower in the EC arm than in the RC arm at the last assessment. Such a reduction in pain is clinically meaningful [40]. However, the posttreatment differences could also be due to the Pygmalion or Hawthorne effects inherent in unblinded clinical research [7]. Nonetheless, based on well-controlled experimental and clinical studies, the added analgesic effect in the two EC arms is in the expected range [19‒25, 27, 28]. The current studies focused on short-term analgesia. As evident from placebo arms in chronic pain studies, placebo effects are long-lasting, suggesting that verbal suggestion should also be beneficial for chronic conditions [41].

The research community can encourage clinicians to adopt this powerful yet simple approach. Other than additional well-designed ecological studies in other painful situations, researchers could share their findings with educators to facilitate the incorporation of this topic in curricula. Healthcare students commonly learn that administering placebos is unethical, but they seldom learn that they could ethically improve outcomes during routine clinical care through verbal suggestion. Disseminating this information in all domains of healthcare will encourage the routine utilization of this simple but potentially efficacious approach [30, 31].

Some limitations deserve consideration. First, study 2’s lack of randomization could contribute to the baseline pain differences. Second, data about nurses’ participation and compliance were not collected. Future studies should use a dyad design to evaluate the potential effect of nurses’ behavior. Third, we did not control for communication between other healthcare professionals and the participants. Fourth, nurses were not blinded for randomization and might have communicated differently (than usual) to RC participants, which could potentially result in insufficient pain relief in the RC arm. Finally, study 2’s heterogenous cohort of different types of surgeries could bias the results.

To conclude, a simple verbal suggestion aimed at increasing patients’ expectations of benefit from analgesic treatment doubles its analgesic effect or, more conservatively, increases it by approximately 30%. This enhanced response could reduce suffering and improve treatment outcomes at no cost, for both the treatment of pain and beyond.

We wish to acknowledge the following colleagues who provided their comments for the draft manuscript: Professors Micha Leshem, Roee Admon, and Irit Weissman Fogel from the University of Haifa; David Yarnitsky from Technion – Israel Institute of Technology; for the statistician, Ms. Sandra Zukerman for reviewing the statistical analyses; and the wonderful Ms. Patricia Boyd for her assistance with English editing.

Both studies received approval from each hospital’s Helsinki Committee (study 1: 0014-23-CMC; study 2: 0128-22-ZIV) and Ethics Committee (University of Haifa, study 1: No. 172/23; study 2: No. 213/23) and were preregistered on Clinicaltrials.gov (study 1: NCT05970029; study 2: NCT06258239). All participants signed informed consents before entering the study.

The authors have no conflicts of interest to declare.

This work was supported by FCT – Fundação para a Ciência e Tecnologia, I.P., by project reference 2020.09061.BD and DOI 10.54499/2020.09061.BD, awarded to M.A.

R.T. planned the studies; oversaw all the studies’ activities, data processing, and data analysis; and wrote the first draft. V.C. and L.I. managed data collection and contributed to the manuscript preparation. M.A. assisted with data processing, data analysis, and the preparation of the Results section of the manuscript. K.B.W. and A.I. assisted with regulatory perspectives and reviewed the manuscript. All the co-authors reviewed the manuscript and approved its final version.

The two anonymized data files of the two studies can be downloaded via this link: https://osf.io/78ypq/?view_only=b4d65ac44fc3429bb7625f4ffb530e69.

1.
Enck
P
,
Bingel
U
,
Schedlowski
M
,
Rief
W
.
The placebo response in medicine: minimize, maximize or personalize
.
Nat Rev Drug Discov
.
2013
;
12
(
3
):
191
204
.
2.
Beecher
HK
.
The powerful placebo
.
J Am Med Assoc
.
1955
;
159
(
17
):
1602
6
.
3.
Bingel
U
.
Placebo 2.0: the impact of expectations on analgesic treatment outcome
.
Pain
.
2020
;
161
(
Suppl 1
):
S48
56
.
4.
Finniss
DG
,
Kaptchuk
TJ
,
Miller
F
,
Benedetti
F
.
Biological, clinical, and ethical advances of placebo effects
.
Lancet
.
2010
;
375
(
9715
):
686
95
.
5.
Colloca
L
,
Enck
P
,
Degrazia
D
.
Relieving pain using dose-extending placebos: a scoping review
.
Pain
.
2016
;
157
(
8
):
1590
8
.
6.
Wager
TD
,
Atlas
LY
.
The neuroscience of placebo effects: connecting context, learning and health
.
Nat Rev Neurosci
.
2015
;
16
(
7
):
403
18
.
7.
Benedetti
F
,
Carlino
E
,
Piedimonte
A
.
Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects
.
Lancet Neurol
.
2016
;
15
(
7
):
736
47
.
8.
Colloca
L
,
Barsky
AJ
.
Placebo and nocebo effects
.
N Engl J Med
.
2020
;
382
(
6
):
554
61
.
9.
Atlas
LY
,
Whittington
RA
,
Lindquist
MA
,
Wielgosz
J
,
Sonty
N
,
Wager
TD
.
Dissociable influences of opiates and expectations on Pain
.
J Neurosci
.
2012
;
32
(
23
):
8053
64
.
10.
Bingel
U
,
Wanigasekera
V
,
Wiech
K
,
Ni Mhuircheartaigh
R
,
Lee
MC
,
Ploner
M
, et al
.
The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil
.
Sci Transl Med
.
2011
;
3
(
70
):
70ra14
.
11.
Frangos
E
,
Čeko
M
,
Wang
B
,
Richards
EA
,
Gracely
JL
,
Colloca
L
, et al
.
Neural effects of placebo analgesia in fibromyalgia patients and healthy individuals
.
Pain
.
2021
;
162
(
2
):
641
52
.
12.
Colloca
L
,
Akintola
T
,
Haycock
NR
,
Blasini
M
,
Thomas
S
,
Phillips
J
, et al
.
Prior therapeutic experiences, not expectation ratings, predict placebo effects: an experimental study in chronic pain and healthy participants
.
Psychother Psychosom
.
2020
;
89
(
6
):
371
8
.
13.
Jensen
KB
,
Kaptchuk
TJ
,
Kirsch
I
,
Raicek
J
,
Lindstrom
KM
,
Berna
C
, et al
.
Nonconscious activation of placebo and nocebo pain responses
.
Proc Natl Acad Sci U S A
.
2012
;
109
(
39
):
15959
64
.
14.
Amanzio
M
,
Benedetti
F
.
Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems
.
J Neurosci
.
1999
;
19
(
1
):
484
94
.
15.
Peerdeman
KJ
,
Van Laarhoven
AIM
,
Keij
SM
,
Vase
L
,
Rovers
MM
,
Peters
ML
, et al
.
Relieving patients’ pain with expectation interventions: a meta-analysis
.
Pain
.
2016
;
157
(
6
):
1179
91
.
16.
Forsberg
JT
,
Martinussen
M
,
Flaten
MA
.
The placebo analgesic effect in healthy individuals and patients: a meta-analysis
.
Psychosom Med
.
2017
;
79
(
4
):
388
94
.
17.
Petersen
GL
,
Finnerup
NB
,
Norskov
KN
,
Grosen
K
,
Pilegaard
HK
,
Benedetti
F
, et al
.
Placebo manipulations reduce hyperalgesia in neuropathic pain
.
Pain
.
2012
;
153
(
6
):
1292
300
.
18.
Schmitz
J
,
Müller
M
,
Stork
J
,
Eichler
I
,
Zöllner
C
,
Flor
H
, et al
.
Positive treatment expectancies reduce clinical pain and perceived limitations in movement ability despite increased experimental pain: a randomized controlled trial on sham opioid infusion in patients with chronic back pain
.
Psychother Psychosom
.
2019
;
88
(
4
):
203
14
.
19.
Tuttle
AH
,
Tohyama
S
,
Ramsay
T
,
Kimmelman
J
,
Schweinhardt
P
,
Bennett
GJ
, et al
.
Increasing placebo responses over time in U.S. clinical trials of neuropathic pain
.
Pain
.
2015
;
156
(
12
):
2616
26
.
20.
Kam-Hansen
S
,
Jakubowski
M
,
Kelley
JM
,
Kirsch
I
,
Hoaglin
DC
,
Kaptchuk
TJ
, et al
.
Labeling of medication and placebo alters the outcome of episodic migraine attacks
.
Sci Transl Med
.
2014
;
6
(
218
):
218
23
.
21.
Amanzio
M
,
Pollo
A
,
Maggi
G
,
Benedetti
F
.
Response variability to analgesics: a role for non-specific activation of endogenous opioids
.
Pain
.
2001
;
90
(
3
):
205
15
.
22.
Patel
SM
,
Stason
WB
,
Legedza
A
,
Ock
SM
,
Kaptchuk
TJ
,
Conboy
L
, et al
.
The placebo effect in irritable bowel syndrome trials: a meta-analysis
.
Neurogastroenterol Motil
.
2005
;
17
(
3
):
332
40
.
23.
Macedo
A
,
Farré
M
,
Baños
JE
.
A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials
.
Eur J Clin Pharmacol
.
2006
;
62
(
3
):
161
72
.
24.
Zhang
W
,
Robertson
J
,
Jones
AC
,
Dieppe
PA
,
Doherty
M
.
The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials
.
Ann Rheum Dis
.
2008
;
67
(
12
):
1716
23
.
25.
Häuser
W
,
Bartram-Wunn
E
,
Bartram
C
,
Reinecke
H
,
Tölle
T
.
Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors
.
Pain
.
2011
;
152
(
8
):
1709
17
.
26.
Kaptchuk
TJ
,
Kelley
JM
,
Conboy
LA
,
Davis
RB
,
Kerr
CE
,
Jacobson
EE
, et al
.
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
.
BMJ
.
2008
;
336
(
7651
):
999
1003
.
27.
Colloca
L
,
Lopiano
L
,
Lanotte
M
,
Benedetti
F
.
Overt versus covert treatment for pain, anxiety, and Parkinson’s disease
.
Lancet Neurol
.
2004
;
3
(
11
):
679
84
.
28.
Benedetti
F
,
Maggi
G
,
Lopiano
L
,
Lanotte
M
,
Rainero
I
,
Vighetti
S
, et al
.
Open versus hidden medical treatments: the patient’s knowledge about a therapy affects the therapy outcome
.
Prev Treat
.
2003
;
6
(
1
).
29.
Egbert
LD
,
Battit
GE
,
Welch
CE
,
Bartlett
MK
.
Reduction of postoperative pain by encouragement and instruction of patients. A study of doctor-patient rapport
.
N Engl J Med
.
1964
;
270
(
16
):
825
7
.
30.
Evers
AWM
,
Colloca
L
,
Blease
C
,
Annoni
M
,
Atlas
LY
,
Benedetti
F
, et al
.
Implications of placebo and nocebo effects for clinical practice: expert consensus
.
Psychother Psychosom
.
2018
;
87
(
4
):
204
10
.
31.
Evers
AWM
,
Colloca
L
,
Blease
C
,
Gaab
J
,
Jensen
KB
,
Atlas
LY
, et al
.
What should clinicians tell patients about placebo and nocebo effects? Practical considerations based on expert consensus
.
Psychother Psychosom
.
2021
;
90
(
1
):
49
56
.
32.
Sánchez Romero
EA
,
Lim
T
,
Villafañe
JH
,
Boutin
G
,
Riquelme Aguado
V
,
Martin Pintado-Zugasti
A
, et al
.
The influence of verbal suggestion on post-needling soreness and pain processing after dry needling treatment: an experimental study
.
Int J Environ Res Public Health
.
2021
;
18
(
8
):
4206
.
33.
Linde
K
,
Witt
CM
,
Streng
A
,
Weidenhammer
W
,
Wagenpfeil
S
,
Brinkhaus
B
, et al
.
The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain
.
Pain
.
2007
;
128
(
3
):
264
71
.
34.
Levine
JD
,
Gordon
NC
.
Influence of the method of drug administration on analgesic response
.
Nature
.
1984
;
312
(
5996
):
755
6
.
35.
Rief
W
,
Wilhelm
M
.
Nocebo and placebo effects and their implications in psychotherapy
.
Psychother Psychosom
.
2024
;
93
(
5
):
298
303
. Published online.
36.
Moustgaard
H
,
Clayton
GL
,
Jones
HE
,
Boutron
I
,
Jørgensen
L
,
Laursen
DRT
, et al
.
Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study
.
BMJ
.
2020
;
368
:
l6802
.
37.
Wang
Y
,
Parpia
S
,
Couban
R
,
Wang
Q
,
Armijo-Olivo
S
,
Bassler
D
, et al
.
Compelling evidence from meta-epidemiological studies demonstrates overestimation of effects in randomized trials that fail to optimize randomization and blind patients and outcome assessors
.
J Clin Epidemiol
.
2024
;
165
:
111211
.
38.
Lipset
CH
.
Engage with research participants about social media
.
Nat Med
.
2014
;
20
(
3
):
231
.
39.
Gracely
RH
,
Dubner
R
,
Deeter
WR
,
Wolskee
PJ
.
Clinicians’ expectations influence placebo analgesia
.
Lancet
.
1985
;
1
(
8419
):
43
.
40.
Farrar
JT
,
Portenoy
RK
,
Berlin
JA
,
Kinman
JL
,
Strom
BL
.
Defining the clinically important difference in pain outcome measures
.
Pain
.
2000
;
88
(
3
):
287
94
.
41.
Quessy
SN
,
Rowbotham
MC
.
Placebo response in neuropathic pain trials
.
Pain
.
2008
;
138
(
3
):
479
83
.